title: IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
authors.affiliation: Bone Marrow Transplantation Unit, C.H.U.J. Minjoz, Besancon, France.
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: T
authors.initials: T
authors.lastname: Fest
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: J
authors.initials: J
authors.lastname: Pariset
authors.forename: M
authors.initials: M
authors.lastname: Delain
authors.forename: L
authors.initials: L
authors.lastname: Voillat
authors.forename: M
authors.initials: M
authors.lastname: Flesch
authors.forename: D
authors.initials: D
authors.lastname: Amsallem
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D014182:Transplantation, Autologous
chemical_list: D007155:Immunologic Factors; D007376:Interleukin-2